Until now, AstraZeneca said it would provide the vaccine “at cost” — around $2 to $3 — for the duration of the pandemic following an agreement with the University of Oxford, which developed the vaccine.
In its update for the three months through September, the company said revenue jumped by about 50%, to a record $9.9 billion.